Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07061288 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia

A Phase 1 study of Schizophrenia, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
8
Study locations

NCT07061288 is a Phase 1 study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 48 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07061288, a Phase 1 study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia

Conditions Studied

Schizophrenia

Interventions

  • DRUG KarXT

Study Locations (8)

Florida

  • Research Centers of America ( Hollywood ) - Hollywood
  • Innovative Clinical Research, Inc. - Miami Lakes

Georgia

  • Atlanta Center for Medical Research - Atlanta
  • CenExel iResearch, LLC - Decatur

California

  • Collaborative Neuroscience Research, LLC - Los Alamitos

Illinois

  • Uptown Research Institute - Chicago

New Jersey

  • Hassman Research Institute Marlton Site - Marlton

Texas

  • Community Clinical Research - Austin

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-09-03
Est. Completion 2027-10-15
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07061288

The ClinicalTrials.gov registry entry for NCT07061288 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which KarXT is the first listed.

NCT07061288 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, Georgia, California.

Frequently Asked Questions

What is clinical trial NCT07061288 about?

NCT07061288 is a clinical study titled "A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia". The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia

What is the current status of trial NCT07061288?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-09-03. Estimated completion is 2027-10-15.

What conditions does trial NCT07061288 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT07061288?

The interventions under investigation include: KarXT (DRUG).

Who is sponsoring clinical trial NCT07061288?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07061288 being conducted?

This trial has 8 study locations across California, Florida, Georgia, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.